Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02806869 · ClinicalTrials.gov registry record · NA
Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment
A NA study, sponsored by University of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
NCT02806869 is a NA study that has completed, run by University of Michigan. The registered enrollment target is 48 participants.
The verdict
NCT02806869, a NA study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
Study Summary
In vivo drug dissolution in the gastrointestinal (GI) tract is largely unmeasured. The purpose of this clinical study was to evaluate the in vivo drug dissolution and systemic absorption of the BCS Class IIa drug ibuprofen under fed and fasted conditions by direct sampling of stomach and small intestinal luminal content. Expanding current knowledge of drug dissolution in vivo will help to establish physiologically relevant in vitro models predictive of drug dissolution.
Interventions
- DRUG Single dose of ibuprofen (800 mg tablet)
- DIETARY_SUPPLEMENT Pulmocare, two 8.0 oz (236.6 mL) cans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02806869
The ClinicalTrials.gov registry entry for NCT02806869 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Single dose of ibuprofen (800 mg tablet) is the first listed.
NCT02806869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02806869 about?
NCT02806869 is a clinical study titled "Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment". In vivo drug dissolution in the gastrointestinal (GI) tract is largely unmeasured. The purpose of this clinical study was to evaluate the in vivo drug dissolution and systemic absorption of the BCS Class IIa drug ibuprofen under fed and fasted conditions by direct sampling of stomach and small intes...
What is the current status of trial NCT02806869?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2015-01. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02806869?
The interventions under investigation include: Single dose of ibuprofen (800 mg tablet) (DRUG), Pulmocare, two 8.0 oz (236.6 mL) cans (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02806869?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.